Where AI Should Actually Earn Its Keep in Biopharma - with Mukhtar Ahmed of Greenstone Biosciences

Welcome, everyone, to the Emerge AI in Business podcast. Mutsar discusses why AI investment in bioforma R&D has concentrated on generating more molecules and candidates, even though the industry's most expensive mistakes happen further downstream in deciding which programs deserve continued capital.

It goes beyond the title with direct discussion of decision, think, where, including: Today's guest is Mutsar Ahmed, Director of Project and Portfolio Strategy at Greenstone Biosciences.

1. 01He argues that AI's greatest value lies in synthesizing fragmented evidence across discovery, regulatory, and commercial teams, while keeping final judgment and accountability with
2. 02A quick note for our audience that the views and opinions expressed by Mokhtar on today's program are his own and do not reflect those of Greenstone Biosciences or its leadership
3. 03But is this pattern of pointing AI at the wrong bottleneck new or is it just the latest version of something that you've seen before?